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I-11 Towards an HIV vaccine what is protective
immunity against HIV infection?
S. Rowland-Jones*. Nufﬁeld Department of Medicine,
Oxford University, John Radcliffe Hospital, Oxford, UK
Following the disappointment experienced after the failure
of the STEP HIV phase II vaccine trial last year, questions
have been raised about whether or not an effective vaccine
to prevent HIV-1 infection can ever be achieved. Some have
argued that the trial should be seen as a product failure
rather than a failure of the entire T-cell vaccine concept,
and that clinical vaccine studies should continue on an
empirical basis. Others have suggested that there should
be a return to basic science in order to deﬁne genuine
correlates of protective immunity against HIV-1 infection.
This presentation will review the current obstacles facing
HIV vaccine development and discuss our understanding of
the requirements for a successful HIV-1 vaccine. Studies of
HIV-2 infection in West Africa will be presented to provide
support for the concept of protective immunity.
I-12 Vaccination against varicella and zoster: history
and experience in the United States
A.A. Gershon*. Department of Pediatrics, Columbia
University Medical Center, New York, USA
Live attenuated varicella vaccine (Oka strain) was
developed in Japan by Professor M. Takahashi and his
colleagues in the early 1970s. This vaccine is the only live
herpesvirus vaccine in use today. While initially designed to
prevent varicella (chickenpox), it is also now employed to
prevent zoster as well, in a somewhat stronger formulation
than that used to prevent varicella. At present the vaccine
is about 85% effective in preventing childhood varicella and
50% effective in preventing zoster in elderly adults with
a past history of natural varicella. To prevent varicella,
the rationale is that immunity to varicella-zoster virus
(VZV) similar to that following natural infection occurs
and prevents subsequent infection with wild type VZV. To
prevent zoster, the rationale is to boost cellular immunity
(CMI) to VZV in individuals who have lost this form of
immunity decades after chickenpox; in this instance the
vaccine is therapeutic.
This presentation will review the safety, immunogenicity,
and protection data for varicella vaccine and the zoster
vaccine. Both of these vaccines have proven to be extremely
safe and effective. Varicella vaccine is being used on a
world wide basis and is used university for children in
a number of countries, including the United States and
Canada. In the United States alone, over 50 million doses
of the vaccine have been distributed for suspceptible
children and adults. In the United States, the incidence
of varicella and its associated morbidity and mortality in
otherwise healthy children has fallen by roughly 80%, not
only in the vaccinated but in the unvaccinated as well,
indicating herd immunity. Zoster results when latent VSV
(after chickenpox or vaccination) reactivates; the incidence
of zoster in vaccines appears to be lower than after the
natural infection. Vaccinated individuals extremely rarely
transmit the Oka strain to others. The duration of immunity
to VZV after vaccination is currently under study, but thus
far appears to be long lasting in most vaccinees.
I-13 Pathogenesis and treatment of bird ﬂu
K.Y. Yuen*. Department of Microbiology, University of Hong
Kong, China
Inﬂuenza A/H5N1 virus kills more than 50% of those infected.
Clinical observation suggested that this disease is not
simply a viral pneumonia, and that all other major organs
could be affected due to a cytokine storm caused by
virus-induced aberrant immune activation. Unlike seasonal
inﬂuenza caused by the human virus, which usually can only
be isolated in the respiratory secretions, the A/H5N1 virus
can also be found in the blood, faeces, and cerebrospinal
ﬂuid. Thus, this so-called cytokine storm could be the
end result of uncontrolled systemic viral infection as in
severe septic shock due to poorly treated Gram negative
bacteraemia. The option of antiviral therapy is very limited,
because resistance to adamantanes is widespread in A/H5N1
isolates from Vietnam and Thailand. Zanamivir is only
likely to be useful for prophylaxis in health care workers,
because it is delivered by inhalation and not expected to
reach therapeutic concentrations in extrapulmonary tissues
or hypoventilated areas of lung consolidation. Intravenous
zanamivir, peramivir and viramidine are not yet available
and intravenous ribavirin has many side effects. Treatment
with oseltamivir did not obviously result in improved survival
and emergence of resistance during treatment is not
uncommon, but there was a trend towards better survival if
given early in the course of illness. Since the lymphopaenia
and serum pro-inﬂammatory cytokine levels correlate
directly with the viral load in respiratory secretions, it
is also reasonable to consider giving immunomodulators to
dampen the cytokine storm. However, the use of steroids
did not improve survival and was associated with signiﬁcant
complications such as hyperglycaemia and superinfection.
In fact, after knockout of pro-inﬂammatory chemokine and
cytokine genes or treatment with steroids, A/H5N1 virus-
infected mouse models showed no signiﬁcant improved
survival. Data from mice models suggest that high dose
of oseltamivir therapy prolonged to more than 8 days,
combination of oseltamivir with amantadine, and use of high
titres of neutralising monoclonal antibody or convalescent
plasma, may improve survival. Cyclooxygenase-2 (COX-2)
was strongly induced in H5N1-infected macrophages in vitro
and in epithelial cells of lung tissue samples obtained
during autopsy of infected patients. COX-2, along with
tumor necrosis factor alpha and other proinﬂammatory
cytokines were hyperinduced in epithelial cells by secretory
factors from H5N1-infected macrophages in vitro. Zanamivir
combined with non-steroidal immunomodulators may have
some effect on improving survival.
